{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024472","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.288489+00:00","generated_at":"2026-06-21T23:35:23.320470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Janux Q3 net loss $16.7M; first patient dosed in JANX007 Phase 1 trial","bullets":["Q3 2022 net loss of $16.7M vs $10.8M prior year; R&D spend $13.7M (up from $8.4M).","Cash and short-term investments $338.8M at Sep 30, 2022, down from $375.0M at Dec 31, 2021.","First patient dosed with JANX007 in Phase 1 trial for prostate cancer; interim data expected 2H 2023.","IND for EGFR-TRACTr (JANX008) on track for 2H 2022; PD-L1xCD28 TRACIr (JANX009) IND planned for 2023.","Strengthened management with new HR head and board addition Winston Kung."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024472","json":"https://secwatch.observer/filing/0000950170-22-024472.json","markdown":"https://secwatch.observer/filing/0000950170-22-024472.md","text":"https://secwatch.observer/filing/0000950170-22-024472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022024472/0000950170-22-024472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022024472/janx-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:35:23.320470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b5877f7528e37f6d009cb31af5c3f27ab3ea17e","claim":"Janux Therapeutics, Inc. reported financial results for the three and nine months ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022024472/0000950170-22-024472-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}